CHMP recommends approval of extension to indication for Briviact in epilepsy.- UCB.

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Briviact (brivaracetam) from UCB. The CHMP adopted an extension to the existing indication as follows: Briviact is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.